TRVN - Trevena, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.5800
-0.0200 (-1.25%)
At close: 4:00PM EDT

1.5700 -0.01 (-0.63%)
After hours: 6:25PM EDT

Stock chart is not supported by your current browser
Previous Close1.6000
Open1.6100
Bid1.5700 x 800
Ask1.6000 x 800
Day's Range1.5400 - 1.6500
52 Week Range0.3820 - 3.5780
Volume1,338,386
Avg. Volume3,964,196
Market Cap145.919M
Beta (3Y Monthly)5.16
PE Ratio (TTM)N/A
EPS (TTM)-0.4180
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.63
Trade prices are not sourced from all markets
  • Trevena (TRVN) Gains As Market Dips: What You Should Know
    Zacks4 days ago

    Trevena (TRVN) Gains As Market Dips: What You Should Know

    Trevena (TRVN) closed at $1.70 in the latest trading session, marking a +1.19% move from the prior day.

  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of TRVN earnings conference call or presentation 13-Mar-19 12:00pm GMT

    Q4 2018 Trevena Inc Earnings Call

  • Will Trevena Continue to Surge Higher?
    Zacks7 days ago

    Will Trevena Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Trevena.

  • Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
    Zacks7 days ago

    Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

    Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

  • ACCESSWIRE7 days ago

    Watch These Four Healthcare Stocks Set The Pace On Tuesday

    Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.

  • Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?
    Zacks9 days ago

    Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?

    Is (TRVN) Outperforming Other Medical Stocks This Year?

  • Trevena says it has 'clear path' to resubmit application for experimental pain medicine
    American City Business Journals11 days ago

    Trevena says it has 'clear path' to resubmit application for experimental pain medicine

    The company could not say exactly when it will resubmit is new drug application for oliceridine, which was rejected by the FDA late last year.

  • PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
    Zacks11 days ago

    PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y

    PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.

  • Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
    Zacks12 days ago

    Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why

    Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.

  • Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
    Zacks12 days ago

    Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

    Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

  • Associated Press14 days ago

    Trevena: 4Q Earnings Snapshot

    On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $232,000 in the period. For the year, the company reported ...

  • GlobeNewswire14 days ago

    Trevena Reports Fourth Quarter and Full Year 2018 Results

    — Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA —  — Successful fundraising extends cash runway into 3Q 2020 —Company to.

  • GlobeNewswire16 days ago

    Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain

    The publication, “APOLLO-1: A randomized placebo- and active-controlled phase III study investigating oliceridine (TRV130), a G protein–biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy,” with lead author, Eugene R Viscusi, M.D.,Professor of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, is available online at https://www.dovepress.com/journal-of-pain-research-archive41. “In this study, oliceridine was found to provide relief that was statistically superior to placebo in patients with moderate-to-severe acute post-surgical pain,” said Dr. Viscusi.

  • ACCESSWIRE22 days ago

    These Four Tech Stocks Could Test March Highs

    As we've seen over the last few years, tech companies have invested resources in artificial intelligence, automation, quantum computing, and augmented reality to pioneer technologies to drive society into the future. ParcelPal Technology Inc (PTNYF) (PKG), Trevena Inc (TRVN), China Finance Online Co. Limited (JRJC), and Luna Innovations Incorporated (LUNA) represent 4 tech stocks on the rise on Monday. The Company is focused on improving the lives of their customers through their on-demand marketplace where customers can purchase what they need and have their goods delivered within an hour.

  • GlobeNewswire23 days ago

    Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019

    CHESTERBROOK, Pa., March 04, 2019 -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.

  • How Much Of Trevena, Inc. (NASDAQ:TRVN) Do Institutions Own?
    Simply Wall St.2 months ago

    How Much Of Trevena, Inc. (NASDAQ:TRVN) Do Institutions Own?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...

  • ACCESSWIRE2 months ago

    Biotech Stocks Set to Pop

    HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...

  • ACCESSWIRE2 months ago

    Top Cannabis and Biotech Stocks To Watch

    HENDERSON, NV / ACCESSWIRE / February 6, 2019 / Cannabis and Biotech are in the middle of a massive comebacks, several small-cap plays in the sectors are prime for investors, here's a few to start researching. ...

  • GlobeNewswire2 months ago

    Trevena to Present at the 21st Annual BIO CEO & Investor Conference

    CHESTERBROOK, Pa., Feb. 05, 2019 -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in CoreLogic, Nasdaq, Nevro, Blue Apron, Unisys, and Trevena — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Trevena to sell stock, makes progress on resubmitting new drug application
    American City Business Journals2 months ago

    Trevena to sell stock, makes progress on resubmitting new drug application

    The Chester County biopharmaceutical expects to initiate a new study for its experimental pain medicine, requested by the FDA, during the first half of this year.

  • ACCESSWIRE2 months ago

    Opioid Abuse and Dependent Therapies, Here is What Travena is Doing to Tackle this Problem

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on smalland mid-cap public companies is issuing a comprehensive report on Trevena, Inc. (TRVN), a biopharmaceutical company that has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. The management strongly believes in the utility of oliceridine as a new analgesic option for the management of moderate to severe acute pain for patients in hospitals or other controlled clinical settings and has laid out a detailed plan to capitalize this opportunity and gain approval for Oliceridine. Trevena was founded to translate Nobel Prize-winning research into a new generation of ground-breaking medicines.

  • GlobeNewswire2 months ago

    Trevena Announces $10 Million Registered Direct Offering of Common Stock

    Trevena, Inc. (TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused institutional investors, pursuant to which Trevena agreed to sell to the purchasers an aggregate of 10,000,000 shares of its common stock at an offering price of $1.00 per share, in a registered direct offering, for gross proceeds of $10.0 million, before deducting placement agent fees and offering expenses payable by Trevena. The offering is expected to close on or about February 1, 2019, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

  • Trevena Jumped by 119.96% Yesterday
    Market Realist2 months ago

    Trevena Jumped by 119.96% Yesterday

    Trevena Stock Soars on Positive Response from FDAStock price jumpOn January 28, Trevena (TRVN) closed at $1.19, which is 119.96% higher than its previous closing price. This spike was in response to the company’s press release that announced the